The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)

Background Several studies have shown that combining immune checkpoint inhibitors (ICIs) with antiangiogenic tyrosine kinase inhibitors is effective for solid tumors, including esophageal squamous cell carcinoma (ESCC). However, most of these studies were focused on immunotherapy-naive patients. Thi...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Xueru Zhu, Xiumei Ma, Hongxuan Li, Ming Zhang, Yan Cheng, Jianguo Wu, Wen Yu, Wen Feng, Lei Zhao, Zhigang Li, Xiaolong Fu, Jun Liu
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Taylor & Francis Group 2025-12-01
Cyfres:	Annals of Medicine
Pynciau:	Anlotinib combination therapeutic regimen esophageal squamous cell carcinoma PD-1 inhibitor progressed on prior ICI
Mynediad Ar-lein:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2443811
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!